The Medical Letter on Drugs and Therapeutics
Edaravone (Radicava) for ALS
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved edaravone (Radicava – Mitsubishi Tanabe Pharma) for treatment of amyotrophic lateral sclerosis (ALS). It is the second drug to be approved in the US for this indication; riluzole (Rilutek, and generics) was approved in 1995.1,2 Edaravone was approved for treatment of ALS as Radicut in Japan and South Korea in 2015. It has been used in Japan and other Asian countries since 2001 for treatment of acute ischemic stroke.

AMYOTROPHIC LATERAL SCLEROSIS — ALS is a progressive degenerative disease of the motor neurons in the brain and spinal cord that results in the inability to initiate and control voluntary muscle movement. Most patients with ALS lose the ability to speak, eat, move, and breathe, and die from respiratory failure within 3-5 years after symptoms first appear. About 90% of patients in the US have the sporadic form of ALS; ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Edaravone (Radicava) for ALS
Article code: 1533b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian